摘要
目的探讨高效抗反转录病毒疗法(HAART)联合扶正抗毒丸对气虚质无症状期人类免疫缺陷病毒(HIV)感染者免疫功能的作用。方法将符合纳入标准的气虚质无症状期HIV感染者根据自愿原则分为HAART组、扶正抗毒丸组,HAART组给予替诺福韦(每次300 mg)^(+)拉米夫定(每次300 mg)^(+)依非韦伦(每次600 mg),每日1次;扶正抗毒丸组在HAART组用药的基础上加服扶正抗毒丸(每次6 g,每日2次)。最终完成研究获得完整数据资料的患者77例,其中HAART组42例、扶正抗毒丸组35例,疗程均为12个月。观察HAART联合扶正抗毒丸对气虚质无症状期HIV感染者CD4^(+)、CD4^(+)CD28^(+)、CD8^(+)、CD8^(+)CD28^(+)、CD8^(+)CD38^(+)、CD8^(+)HLA-DR^(+)T细胞绝对计数及HIV-RNA的作用。结果与本组治疗前比较,两组患者CD4^(+)CD28^(+)T细胞绝对计数升高(Z=-2.363,-4.406,P<0.05,P<0.01),HIV-RNA<100 copy/mL所占百分比均增加(χ^(2)=72.593,62.279,P<0.01)。HAART组CD8^(+)、CD8^(+)CD28^(+)、CD8^(+)HLA-DR^(+)T细胞绝对计数均显著降低(Z=-2.788,-4.395,-2.369,P<0.05,P<0.01),扶正抗毒丸组CD8^(+)、CD8^(+)HLA-DR^(+)T细胞绝对计数均显著降低(Z=-3.276,-2.334,P<0.05,P<0.01)。治疗后,与HARRT组比较,扶正抗毒丸组CD4^(+)CD28^(+)T、CD8^(+)CD28^(+)T细胞绝对计数显著升高(Z=-3.437,-1.969,P<0.01,P<0.05)。HAART组不良事件发生率9.52%(4/42)与扶正抗毒丸组的5.71%(2/35)比较差异无统计学意义(χ^(2)=0.038,P=0.846)。结论HAART联合扶正抗毒丸能有效增加CD4^(+)CD28^(+)T和稳定CD8^(+)CD28^(+)T细胞绝对计数,且安全性高。
Objective To explore the effect of highly active antiretroviral therapy(HAART)combined with Fuzheng Kangdu Pill(FZKDP)on the immune function of human immunodeficiency virus(HIV)-infected patients in the asymptomatic stage of Qi deficiency constitution.Methods And 77 HIV-infected patients in the asymptomatic stage of Qi deficiency constitution with complete clinical data were assigned to the HAART group and the FZKDP group according to the voluntary principle,with 42 patients in HAART group and 35 patients in FZKDP group.The HAART group was given tenofovir(300 mg each time);lamivudine(300 mg each time);efavirenz(600 mg each time),once a day,and the FZKDP group was given FZKDP on the basis of the HAART group(6 g each time),twice a day.All patients received drug treatment for 12 months,and the effects of HAART combined with FZKDP on HIV patients was evaluated by measuring the T lymphocyte counts of CD4^(+),CD4^(+)CD28^(+),CD8^(+)CD28^(+),CD8^(+)CD38^(+),CD8^(+)HLA-DR;and the HIV-RNA.Results Compared with before treatment,the count of CD4^(+)CD28^(+)T cells was increased(Z=-2.363,-4.406,P<0.05,P<0.01),and the percentage of HIV-RNA<100 copy/mL was increased in two groups(χ^(2)=72.593,62.279,P<0.01).The counts of CD8^(+),CD8^(+)CD28^(+)and CD8^(+)HLA-DR;T cells in HAART group significantly decreased(Z=-2.788,-4.395,-2.369,P<0.05,P<0.01).The count of CD8^(+)and CD8^(+)HLA-DR;T cells in FZKDP group significantly decreased(Z=-3.276,-2.334,P<0.05,P<0.01).After treatment,compared with HAART group,the counts of CD4^(+)CD28^(+)T and CD8^(+)CD28^(+)T cells in FZKDP group increased(Z=-3.437,-1.969,P<0.01,P<0.05).There was no significant difference in the incidence of adverse events between the HAART group(9.52%,4/42)and the FZKDP group(5.71%,2/35,χ^(2)=0.038,P=0.846).Conclusions HAART combined with FZKDP can effectively increase the absolute counts of CD4^(+)CD28^(+)T and stable CD8^(+)CD28^(+)T cells with high safety.
作者
李钦
王莉
LI Qin;WANG Li(Basic Medical College,Yunnan University of Traditional Chinese Medicine,Kunming,650500;Postdoctoral Research Station,Yunnan Hospital of Chinese Medicine,Kunming,650021;Chinese Medicine Research Center for AIDS,Yunnan Academy of Chinese Medicine,Kunming,650223)
出处
《中国中西医结合杂志》
CAS
CSCD
北大核心
2022年第4期419-424,共6页
Chinese Journal of Integrated Traditional and Western Medicine
基金
云南省科技计划重点项目(No.2019FA036)
云南省教育厅科学研究基金教师类项目(No.2020J0290)
国家自然科学基金地区基金项目(No.81760831)
“十三五”艾滋病和病毒性肝炎等重大传染病防治科技重大专项(No.2017ZX10205502-002)。